The efficacy and safety of low-dose rituximab in the treatment of pemphigus vulgaris: a cohort study
Background Rituximab (RTX) is considered the first-line treatment for pemphigus vulgaris (PV), which is a B-cell-mediated acquired autoimmune disease. However, no consensus on the optimum dosage has been achieved.Objectives To investigate the efficacy and safety of low-dose RTX (a single infusion of...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | Journal of Dermatological Treatment |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/09546634.2024.2302071 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850115085690732544 |
|---|---|
| author | Xingli Zhou Tongying Zhan Xiaoxi Xu Tianjiao Lan Hongxiang Hu Yuxi Zhou Dengmei Xia Jinqiu Wang Yiyi Wang Yue Xiao Wei Li |
| author_facet | Xingli Zhou Tongying Zhan Xiaoxi Xu Tianjiao Lan Hongxiang Hu Yuxi Zhou Dengmei Xia Jinqiu Wang Yiyi Wang Yue Xiao Wei Li |
| author_sort | Xingli Zhou |
| collection | DOAJ |
| description | Background Rituximab (RTX) is considered the first-line treatment for pemphigus vulgaris (PV), which is a B-cell-mediated acquired autoimmune disease. However, no consensus on the optimum dosage has been achieved.Objectives To investigate the efficacy and safety of low-dose RTX (a single infusion of 500 mg) for the treatment of PV, a cohort study was conducted for patients with PV, along with a 12-month follow-up following the administration of RTX.Methods Patients with moderate or severe PV were divided into group A (low-dose RTX combined with corticosteroids) and group B (corticosteroids alone). Data on complete remission (CR) rates, doses of corticosteroids, cumulative doses of corticosteroids at the third, sixth, and twelfth months, pemphigus disease area index and adverse effects (AEs) were collected.Results Forty-four patients with moderate or severe PV were enrolled in this study (19 in group A and 25 in group B). Patients treated with low-dose RTX had higher CR rates, lower doses of corticosteroids at the third, sixth, and twelfth months, lower cumulative doses of corticosteroids at the sixth and twelfth months, and fewer AEs than those who received corticosteroids alone.Conclusions This study indicated that low-dose RTX may be a beneficial and secure therapy option for patients with moderate to severe PV. |
| format | Article |
| id | doaj-art-9117d3c6162e4081a160aa855a8241e5 |
| institution | OA Journals |
| issn | 0954-6634 1471-1753 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Journal of Dermatological Treatment |
| spelling | doaj-art-9117d3c6162e4081a160aa855a8241e52025-08-20T02:36:40ZengTaylor & Francis GroupJournal of Dermatological Treatment0954-66341471-17532024-12-0135110.1080/09546634.2024.2302071The efficacy and safety of low-dose rituximab in the treatment of pemphigus vulgaris: a cohort studyXingli Zhou0Tongying Zhan1Xiaoxi Xu2Tianjiao Lan3Hongxiang Hu4Yuxi Zhou5Dengmei Xia6Jinqiu Wang7Yiyi Wang8Yue Xiao9Wei Li10Department of Dermatology, Rare Diseases Center, West China Hospital, Sichuan University, Chengdu, ChinaWest China School of Medicine, West China Hospital, Sichuan University, Chengdu, ChinaDepartment of Dermatology, Rare Diseases Center, West China Hospital, Sichuan University, Chengdu, ChinaWest China School of Medicine, West China Hospital, Sichuan University, Chengdu, ChinaDepartment of Dermatology, Rare Diseases Center, West China Hospital, Sichuan University, Chengdu, ChinaDepartment of Dermatology, Rare Diseases Center, West China Hospital, Sichuan University, Chengdu, ChinaWest China School of Medicine, West China Hospital, Sichuan University, Chengdu, ChinaDepartment of Outpatient, West China Hospital, Sichuan University, Chengdu, ChinaDepartment of Dermatology, Rare Diseases Center, West China Hospital, Sichuan University, Chengdu, ChinaDepartment of Dermatology, Rare Diseases Center, West China Hospital, Sichuan University, Chengdu, ChinaDepartment of Dermatology, Rare Diseases Center, West China Hospital, Sichuan University, Chengdu, ChinaBackground Rituximab (RTX) is considered the first-line treatment for pemphigus vulgaris (PV), which is a B-cell-mediated acquired autoimmune disease. However, no consensus on the optimum dosage has been achieved.Objectives To investigate the efficacy and safety of low-dose RTX (a single infusion of 500 mg) for the treatment of PV, a cohort study was conducted for patients with PV, along with a 12-month follow-up following the administration of RTX.Methods Patients with moderate or severe PV were divided into group A (low-dose RTX combined with corticosteroids) and group B (corticosteroids alone). Data on complete remission (CR) rates, doses of corticosteroids, cumulative doses of corticosteroids at the third, sixth, and twelfth months, pemphigus disease area index and adverse effects (AEs) were collected.Results Forty-four patients with moderate or severe PV were enrolled in this study (19 in group A and 25 in group B). Patients treated with low-dose RTX had higher CR rates, lower doses of corticosteroids at the third, sixth, and twelfth months, lower cumulative doses of corticosteroids at the sixth and twelfth months, and fewer AEs than those who received corticosteroids alone.Conclusions This study indicated that low-dose RTX may be a beneficial and secure therapy option for patients with moderate to severe PV.https://www.tandfonline.com/doi/10.1080/09546634.2024.2302071Pemphigus vulgarislow-doserituximabcorticosteroidsadverse events |
| spellingShingle | Xingli Zhou Tongying Zhan Xiaoxi Xu Tianjiao Lan Hongxiang Hu Yuxi Zhou Dengmei Xia Jinqiu Wang Yiyi Wang Yue Xiao Wei Li The efficacy and safety of low-dose rituximab in the treatment of pemphigus vulgaris: a cohort study Journal of Dermatological Treatment Pemphigus vulgaris low-dose rituximab corticosteroids adverse events |
| title | The efficacy and safety of low-dose rituximab in the treatment of pemphigus vulgaris: a cohort study |
| title_full | The efficacy and safety of low-dose rituximab in the treatment of pemphigus vulgaris: a cohort study |
| title_fullStr | The efficacy and safety of low-dose rituximab in the treatment of pemphigus vulgaris: a cohort study |
| title_full_unstemmed | The efficacy and safety of low-dose rituximab in the treatment of pemphigus vulgaris: a cohort study |
| title_short | The efficacy and safety of low-dose rituximab in the treatment of pemphigus vulgaris: a cohort study |
| title_sort | efficacy and safety of low dose rituximab in the treatment of pemphigus vulgaris a cohort study |
| topic | Pemphigus vulgaris low-dose rituximab corticosteroids adverse events |
| url | https://www.tandfonline.com/doi/10.1080/09546634.2024.2302071 |
| work_keys_str_mv | AT xinglizhou theefficacyandsafetyoflowdoserituximabinthetreatmentofpemphigusvulgarisacohortstudy AT tongyingzhan theefficacyandsafetyoflowdoserituximabinthetreatmentofpemphigusvulgarisacohortstudy AT xiaoxixu theefficacyandsafetyoflowdoserituximabinthetreatmentofpemphigusvulgarisacohortstudy AT tianjiaolan theefficacyandsafetyoflowdoserituximabinthetreatmentofpemphigusvulgarisacohortstudy AT hongxianghu theefficacyandsafetyoflowdoserituximabinthetreatmentofpemphigusvulgarisacohortstudy AT yuxizhou theefficacyandsafetyoflowdoserituximabinthetreatmentofpemphigusvulgarisacohortstudy AT dengmeixia theefficacyandsafetyoflowdoserituximabinthetreatmentofpemphigusvulgarisacohortstudy AT jinqiuwang theefficacyandsafetyoflowdoserituximabinthetreatmentofpemphigusvulgarisacohortstudy AT yiyiwang theefficacyandsafetyoflowdoserituximabinthetreatmentofpemphigusvulgarisacohortstudy AT yuexiao theefficacyandsafetyoflowdoserituximabinthetreatmentofpemphigusvulgarisacohortstudy AT weili theefficacyandsafetyoflowdoserituximabinthetreatmentofpemphigusvulgarisacohortstudy AT xinglizhou efficacyandsafetyoflowdoserituximabinthetreatmentofpemphigusvulgarisacohortstudy AT tongyingzhan efficacyandsafetyoflowdoserituximabinthetreatmentofpemphigusvulgarisacohortstudy AT xiaoxixu efficacyandsafetyoflowdoserituximabinthetreatmentofpemphigusvulgarisacohortstudy AT tianjiaolan efficacyandsafetyoflowdoserituximabinthetreatmentofpemphigusvulgarisacohortstudy AT hongxianghu efficacyandsafetyoflowdoserituximabinthetreatmentofpemphigusvulgarisacohortstudy AT yuxizhou efficacyandsafetyoflowdoserituximabinthetreatmentofpemphigusvulgarisacohortstudy AT dengmeixia efficacyandsafetyoflowdoserituximabinthetreatmentofpemphigusvulgarisacohortstudy AT jinqiuwang efficacyandsafetyoflowdoserituximabinthetreatmentofpemphigusvulgarisacohortstudy AT yiyiwang efficacyandsafetyoflowdoserituximabinthetreatmentofpemphigusvulgarisacohortstudy AT yuexiao efficacyandsafetyoflowdoserituximabinthetreatmentofpemphigusvulgarisacohortstudy AT weili efficacyandsafetyoflowdoserituximabinthetreatmentofpemphigusvulgarisacohortstudy |